Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hopes For Glaxo’s MAGE-A3 Vaccine Grow Dim As Trial Misses Endpoint

This article was originally published in The Pink Sheet Daily

Executive Summary

Glaxo’s vaccine fails co-primary endpoint in Phase III DERMA study of melanoma – trial is allowed to continue but hopes for success are not high. Top-line release raises specter that drug could become yet another failed cancer vaccine.

You may also be interested in...



Three Strikes But Not Out: GSK Maneuvers Through A Third R&D Setback

GlaxoSmithKline’s decision to end a Phase III trial testing the cancer immunotherapy MAGE-A3 in NSCLC is no surprise, following disappointing results in two trials, but coupled with other disappointing R&D news it puts more pressure on the company to deliver on its respiratory launches.

Three Strikes But Not Out: GSK Maneuvers Through A Third R&D Setback

GlaxoSmithKline’s decision to end a Phase III trial testing the cancer immunotherapy MAGE-A3 in NSCLC is no surprise, following disappointing results in two trials, but coupled with other disappointing R&D news it put more pressure on the company to deliver on its respiratory launches.

Big Pharma Explores New Frontier Of Lung Cancer Immunotherapy

Lung cancer wasn’t viewed traditionally as a tumor that would respond to immunotherapy. But with checkpoint inhibitor data looking promising, big pharma is diving in and prioritizing the disease, reeled in by the large patient population and high unmet need.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS076337

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel